XML 75 R58.htm IDEA: XBRL DOCUMENT
v3.20.4

Collaborations - Additional Information (Detail) - USD ($) $ in Thousands |  | 1 Months Ended | 12 Months Ended |
--- | --- | --- | --- | ---
Dec. 18, 2019 | Jan. 31, 2020 | Dec. 31, 2018 | Feb. 28, 2018 | Dec. 31, 2020 | Dec. 08, 2016
Revenue Recognition Multiple Deliverable Arrangements [Line Items] |  |  |  |  |  |
License and collaboration revenue |  |  |  |  | $ 20,948 |
License |  |  |  |  |  |
Revenue Recognition Multiple Deliverable Arrangements [Line Items] |  |  |  |  |  |
License and collaboration revenue |  |  |  |  | 15,100 |
License | Transfer of Exclusive License and Related Know-How |  |  |  |  |  |
Revenue Recognition Multiple Deliverable Arrangements [Line Items] |  |  |  |  |  |
License and collaboration revenue |  |  |  |  | 15,000 |
Exclusive License |  |  |  |  |  |
Revenue Recognition Multiple Deliverable Arrangements [Line Items] |  |  |  |  |  |
License and collaboration revenue |  |  |  |  | 100 |
Collaboration |  |  |  |  |  |
Revenue Recognition Multiple Deliverable Arrangements [Line Items] |  |  |  |  |  |
License and collaboration revenue |  |  |  |  | 5,848 |
Collaboration | Reimbursable Out-of-Pocket and Personnel Costs Incurred Related to Research Services |  |  |  |  |  |
Revenue Recognition Multiple Deliverable Arrangements [Line Items] |  |  |  |  |  |
License and collaboration revenue |  |  |  |  | 5,800 |
Pfizer Inc | Collaboration Agreement |  |  |  |  |  |
Revenue Recognition Multiple Deliverable Arrangements [Line Items] |  |  |  |  |  |
Milestone payment |  |  |  | $ 1,000 | 0 |
Pfizer Inc | Collaboration Agreement | Maximum |  |  |  |  |  |
Revenue Recognition Multiple Deliverable Arrangements [Line Items] |  |  |  |  |  |
Contingent cash payments upon achievement of certain clinical, regulatory and commercial milestones |  |  |  |  |  | $ 17,500
ISU Abxis | Amended and Restated License Agreement |  |  |  |  |  |
Revenue Recognition Multiple Deliverable Arrangements [Line Items] |  |  |  |  |  |
Regulatory and development milestone payment |  |  | $ 2,500 |  | 0 |
ISU Abxis | Amended and Restated License Agreement | Maximum |  |  |  |  |  |
Revenue Recognition Multiple Deliverable Arrangements [Line Items] |  |  |  |  |  |
Milestone payment |  |  | 19,500 |  | 0 |
Commercial milestone payments |  |  | $ 17,000 |  | $ 0 |
Biogen | License and Collaboration Agreement (the “Biogen Agreement”) |  |  |  |  |  |
Revenue Recognition Multiple Deliverable Arrangements [Line Items] |  |  |  |  |  |
Research services | 30 months |  |  |  |  |
Research services option to extend | 12 months |  |  |  |  |
Biogen | Exclusive License |  |  |  |  |  |
Revenue Recognition Multiple Deliverable Arrangements [Line Items] |  |  |  |  |  |
Up-front payments received |  | $ 15,000 |  |  |  |
Biogen | Exclusive License | Maximum |  |  |  |  |  |
Revenue Recognition Multiple Deliverable Arrangements [Line Items] |  |  |  |  |  |
Development and sales milestone payments |  | $ 340,000 |  |  |  |

X
- Definition Commercial milestone payments. + References No definition available. + Details
Name: | cbio_CommercialMilestonePayments
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Development milestones payment Receivable. + References No definition available. + Details
Name: | cbio_DevelopmentMilestonesPaymentReceivable
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone contingent cash payments obligation. + References No definition available. + Details
Name: | cbio_MilestoneContingentCashPaymentsObligation
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Milestone payments. + References No definition available. + Details
Name: | cbio_MilestonePayments
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Regulatory and development milestone payment. + References No definition available. + Details
Name: | cbio_RegulatoryAndDevelopmentMilestonePayment
Namespace Prefix: | cbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Research services agreement option to extend. + References No definition available. + Details
Name: | cbio_ResearchServicesAgreementOptionToExtend
Namespace Prefix: | cbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research services. + References No definition available. + Details
Name: | cbio_ResearchServicesAgreementTerm
Namespace Prefix: | cbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cash received from licensees for license fees during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromLicenseFeesReceived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=cbio_LicenseRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cbio_ExclusiveLicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cbio_CollaborationRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cbio_PfizerIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TransactionTypeAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cbio_IsuAbxisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TransactionTypeAxis=cbio_AmendedAndRestatedLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cbio_BiogenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TransactionTypeAxis=cbio_LicenseAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TransactionTypeAxis=cbio_ExclusiveLicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |